220 related articles for article (PubMed ID: 31837576)
61. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
62. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
63. Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
Lala M; Chirovsky D; Cheng JD; Mayawala K
Oral Oncol; 2018 Sep; 84():108-120. PubMed ID: 30115469
[TBL] [Abstract][Full Text] [Related]
64. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.
Patel B; Saba NF
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298761
[TBL] [Abstract][Full Text] [Related]
65. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial.
Perri F; Longo F; Fusco R; D'Alessio V; Aversa C; Pavone E; Pontone M; Marciano ML; Villano S; Franco P; Togo G; Fazio GR; Ordano D; Maglitto F; Salzano G; Maglione MG; Guida A; Ionna F
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34064511
[TBL] [Abstract][Full Text] [Related]
66. Exceptional response to cetuximab monotherapy after failure of immunotherapy with a checkpoint inhibitor in a patient with metastatic head and neck squamous cell cancer: case report and review of the literature.
Bloomer CH; Gavrila E; Burcher KM; Kalada JM; Chang MJ; Gebeyehu RR; Asare E; Khoury LM; Kinney R; Frizzell B; Sullivan CA; Bunch PM; Porosnicu M
Ther Adv Med Oncol; 2023; 15():17588359231193722. PubMed ID: 37667781
[TBL] [Abstract][Full Text] [Related]
67. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.
Smyth EC; Gambardella V; Cervantes A; Fleitas T
Ann Oncol; 2021 May; 32(5):590-599. PubMed ID: 33609722
[TBL] [Abstract][Full Text] [Related]
68. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Borel C; Jung AC; Burgy M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32967162
[TBL] [Abstract][Full Text] [Related]
69. Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Borcoman E; Marret G; Le Tourneau C
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073885
[TBL] [Abstract][Full Text] [Related]
70. Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?
von der Grün J; Rödel F; Brandts C; Fokas E; Guckenberger M; Rödel C; Balermpas P
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30987257
[TBL] [Abstract][Full Text] [Related]
71. Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity.
Patil VM; Noronha V; Joshi A; Abhyankar A; Menon N; Dhumal S; Prabhash K
Oral Oncol; 2020 Jun; 105():104673. PubMed ID: 32272385
[TBL] [Abstract][Full Text] [Related]
72. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer.
Nakano T; Yasumatsu R; Hashimoto K; Kuga R; Hongo T; Yamamoto H; Matsuo M; Wakasaki T; Jiromaru R; Manako T; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Uryu H; Nakashima T; Tamae A; Tanaka R; Taura M; Takeuchi T; Yoshida T; Nakagawa T
In Vivo; 2022; 36(2):979-984. PubMed ID: 35241559
[TBL] [Abstract][Full Text] [Related]
73. Immunotherapy and Targeted Therapy in the Management of Oral Cancers.
Dutta S; Singhal S; Shah RB; Haque M
Crit Rev Oncog; 2022; 27(4):23-37. PubMed ID: 37199300
[TBL] [Abstract][Full Text] [Related]
74. Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.
Saada-Bouzid E; Le Tourneau C
Front Oncol; 2019; 9():74. PubMed ID: 30815390
[TBL] [Abstract][Full Text] [Related]
75. NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers.
Brooker RC; Schache AG; Sacco JJ
Br J Oral Maxillofac Surg; 2021 Oct; 59(8):959-962. PubMed ID: 34325944
[TBL] [Abstract][Full Text] [Related]
76. Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases.
Houessinon A; Moreira A; Bettoni J; Schoonaker M; Sauzay C; Galmiche A; Coutte A; Biet A; Krzisch C; Chauffert B
Case Rep Oncol; 2020; 13(2):835-842. PubMed ID: 32884527
[TBL] [Abstract][Full Text] [Related]
77. The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer.
Tinhofer I; Budach V; Jöhrens K; Keilholz U
Cancers Head Neck; 2016; 1():8. PubMed ID: 31093338
[TBL] [Abstract][Full Text] [Related]
78. Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy.
Perri F; Ionna F; Longo F; Della Vittoria Scarpati G; De Angelis C; Ottaiano A; Botti G; Caponigro F
Transl Oncol; 2020 Feb; 13(2):262-274. PubMed ID: 31869751
[TBL] [Abstract][Full Text] [Related]
79. Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.
Gutiérrez Calderón V; Cantero González A; Gálvez Carvajal L; Aguilar Lizarralde Y; Rueda Domínguez A
Ther Adv Med Oncol; 2021; 13():1758835920984061. PubMed ID: 33747147
[TBL] [Abstract][Full Text] [Related]
80. Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.
Teixeira Farinha H; Digklia A; Schizas D; Demartines N; Schäfer M; Mantziari S
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
